Today: 17 May 2026
Meta vs Google vs Apple Stock Price Forecast: Big Tech Earnings Week Could Shift the AI Trade

Meta vs Google vs Apple Stock Price Forecast: Big Tech Earnings Week Could Shift the AI Trade

New York, April 26, 2026, 07:43 EDT

Alphabet’s announcement that it could pour as much as $40 billion into Anthropic is adding fuel to the Meta-Google-Apple stock rivalry right before the trio steps up for earnings. Wall Street’s not debating the appeal of artificial intelligence anymore—it’s watching to see who can actually translate those AI investments into sales, profits, or both.

The schedule is tight. Meta Platforms and Alphabet both release earnings Wednesday, while Apple follows on Thursday—three giants packed into a brief reporting stretch. According to Reuters, over a third of the S&P 500 is set to announce results next week, and much of the market’s attention is zeroed in on what Meta, Alphabet, Microsoft, and Amazon are spending on data centers and AI infrastructure.

This isn’t shaping up like your typical earnings week; it’s more about whether the AI-fueled rally holds up. “Big week for confirmation of the rally,” is how Anthony Saglimbene, chief market strategist at Ameriprise, put it, according to Reuters. Reuters

Meta shares last traded at $675.03, a 2.4% gain from the prior close. Alphabet Class A finished at $344.40, up 1.6%. Apple slipped, ending at $271.06, down 0.9%. All quotes reflect trades executed after Friday’s U.S. session, with the market shut for the weekend.

Meta stands out on Wall Street’s price targets, still offering the biggest implied upside. According to MarketBeat, analysts have pegged Meta’s average 12-month target at $837.09—about 23.92% above current levels. Apple’s consensus comes in at $303.06, or an 11.80% gain, while Alphabet’s sits at $369.67, up 7.34%. Of course, these targets are just analyst estimates, not guarantees, and part of the gap comes down to how much each stock has already climbed.

Meta stands out as the clearest margin play right now. The Facebook and Instagram parent is scheduled to post its first-quarter numbers after the bell on April 29. Earlier this month, Reuters reported the company is preparing to cut nearly 8,000 jobs—roughly 10% of its global staff—starting May 20, as Meta chases greater efficiency through its AI push.

AI scale and cloud demand are increasingly at the center of Alphabet’s story, nudging search ads out of the spotlight. The company has set its first-quarter earnings call for April 29 at 4:30 p.m. ET. Meanwhile, Reuters on Friday pointed to Google’s $10 billion cash commitment to Anthropic at a $350 billion valuation, and there’s another $30 billion possible, depending on performance targets.

Google shares could be headed for a sharper move than normal, with options markets implying swings of up to 5% either way before the week wraps up, according to Investopedia. Citi analysts, meanwhile, bumped their price target to $405 from $390.

Apple stands out as the straightforward consumer-hardware benchmark, though the outlook isn’t as clear-cut. According to Reuters, Apple’s quarterly results land April 30, right after the CEO transition made investors rethink what’s next for the tech giant. “Tim Cook did an amazing job,” said Rick Meckler, partner at Cherry Lane Investments. Reuters

Rivalry is fierce. Microsoft and Amazon drop results in the same window as Meta and Alphabet, with Amazon’s Anthropic stake putting even more focus on AI muscle — chips, power, data centers, cloud deals. Capital expenditures, or capex, go into assets like data centers and servers that have staying power; investors are watching to see if those bets pay off.

The risk here isn’t hard to spot: disappointing earnings, or management ramping up capex without a corresponding jump in ads, cloud, iPhone, or AI revenues, could yank away the premium these stocks have been trading on. Reuters flagged next week’s setup—Federal Reserve decision, Iran conflict, energy prices—as a trio of threats that can quickly knock down high-flying growth names.

At this point, Meta leads on analyst-implied upside, while Apple’s projected range is narrower but steadier. Alphabet? It’s riding the newest AI catalyst. Stock action reflects the same themes, just less neatly: Google shares are on the move, Meta’s got the widest gap to those forecasts, and Apple still needs to show it’s not just rolling out another iPhone upgrade as its main growth story.

Stock Market Today

  • Aquestive Therapeutics Reports Strong Q1 Results, Analysts Maintain 2026 Forecasts
    May 16, 2026, 8:17 PM EDT. Aquestive Therapeutics (NASDAQ:AQST) posted strong first-quarter results with revenues of $14 million, surpassing analyst expectations by 33%, and smaller-than-expected losses of $0.07 per share. Despite the upbeat quarter, analysts forecast a 3.6% revenue decline in 2026 to $48.4 million and a 15% decrease in losses to $0.47 per share. The consensus price target remains steady at $8.89, suggesting the stock is trading in line with expectations amid continuing losses. Revenue growth is expected to slow significantly compared to the past five years, lagging behind an 8% annual growth forecast for the wider industry. Investors face mixed views on valuation, with targets ranging from $6.00 to $11.00 per share.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Microsoft vs Oracle vs Google Stock: Price Forecasts Reveal a Split in the AI Cloud Race
Previous Story

Microsoft vs Oracle vs Google Stock: Price Forecasts Reveal a Split in the AI Cloud Race

Lockheed Martin Gets Golden Dome Shot as $3.2 Billion Space Shield Race Opens
Next Story

Lockheed Martin Gets Golden Dome Shot as $3.2 Billion Space Shield Race Opens

Go toTop